Galmed Pharmaceuticals Ltd. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company stated about its new product Aramchol in the following article, “Early in the development, it was observed that Aramchol reduced liver fat infiltration in animals fed a high fat, lithogenic diet2. This effect was confirmed in other animal models and the development plan was modified according to these findings, as fatty liver is an unmet need.” Read the full article.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. The Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel. [Source: MarketWatch]
Company Website: http://galmedpharma.com